Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration
Top Cited Papers
- 1 January 2019
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 126 (1), 55-63
- https://doi.org/10.1016/j.ophtha.2018.07.028
Abstract
No abstract availableKeywords
Funding Information
- American Academy of Ophthalmology
This publication has 41 references indexed in Scilit:
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE StudyOphthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Cost Effectiveness of Treatments for Wet Age-Related Macular DegenerationPharmacoEconomics, 2011
- Cost‐utility analysis of bevacizumab versus ranibizumab in neovascular age‐related macular degeneration using a Markov modelJournal of Evaluation in Clinical Practice, 2010
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 ResultsAmerican Journal of Ophthalmology, 2008
- Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumabEye, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004